His Excellency Mohamed Haji Al Khoori is the Director General of the Khalifa Bin Zayed Al Nahyan Foundation. He joined the Foundation at its inception in 2007. Previously, he established the Medical Department at the Crown Prince's Court of His Highness Sheikh Khalifa Bin Zayed Al Nahyan where he served as Medical Director, arranging for patients to travel overseas for treatment. Mohamed Haji Al Khoori graduated from California State University at San Bernardino, with a major in Economics.

Peter Fedichev is the co-founder and CEO of Gero, a biotech company pioneering AI-driven therapeutics to extend human healthspan and combat age-related diseases. He is one of the few global experts combining two rare qualities — a scientist with internationally recognized fundamental discoveries and a successful entrepreneur leading a company that is reshaping the longevity industry. Peter is also a Professor at the National University of Singapore (ranked among the world’s Top 10 universities). His rare public appearances are considered key events that help shape the scientific and business agenda of the longevity field.

Dr Madhu Sasidhar is the President & CEO of Apollo Hospitals. Dr Sasidhar is a practising physician with US board certifications in internal medicine, pulmonary, and critical care medicine. He completed his medical education at JIPMER, Pondicherry. Following a residency in Internal Medicine at St Luke’s Roosevelt Hospital in New York City, he completed fellowships in Pulmonary and Critical Care Medicine at Yale University, New Haven, USA. He received his Global Executive Master's in Business Administration from INSEAD, Fontainebleau, France. Dr Sasidhar served as President of Cleveland Clinic Tradition Hospital. Before that, he was the Chief Medical Officer at Cleveland Clinic Abu Dhabi and Enterprise Section Head for Respiratory Care for the Cleveland Clinic Health System. Dr Sasidhar has published numerous book chapters, journal and peer-reviewed articles, abstracts, and presentations and has been invited to speak on various topics at many industry events. He holds a patent through Cleveland Clinic Innovations for a technology he invented that was subsequently commercialised. Dr Sasidhar is also a self-taught computer programmer with expertise in big data platforms.

John M. Cunningham, MD, is an internationally known expert in the treatment and research of childhood cancers and blood diseases. He has particular expertise in treating leukemia, lymphoma, immunodeficiencies,
sickle cell disease and thalassemia. He is a recognized leader in the field of pediatric stem cell transplantation and has developed novel uses for this life-saving treatment. An active researcher, Dr. Cunningham is studying the biology and therapy of hemoglobinopathies,
hematopoiesis and the leukemia stem cell, transcriptional mechanisms operative during the development of vertebrate organisms, and the development of clinical trials for the treatment of leukemia and genetic diseases. Over his distinguished career, Dr. Cunningham's
research has received support from the National Heart, Lung, and Blood Institute, the American Society of Hematology, and other prominent scientific organizations. He is a member of the scientific council of the American Cancer Society, and a member of the
editorial board of The Oncologist.

Dr. Ayas is the Associate Dean for International Medicine at the School of Medicine and Health Sciences (SMHS), founder and Executive Director of the Office of International Medicine Programs; Director of the Global Health Scholarly Concentration, Director of three interdisciplinary medicine courses; and Professorial Lecturer of Global Health, in the Milken Institute School of Public Health at The George Washington University (GW). As Associate Dean, Dr. Ayas serves as a member of the senior leadership group in implementing strategic planning and oversight of international health and medical education and research training programs and projects. She represents the SMHS on all international projects, work groups and committees, both domestically and abroad. As Executive Director, Dr. Ayas has formed more than 70 global strategic partnerships and affiliations, and she has developed and implemented several international medical education and research training programs. These programs include the MD Program for International Students; the International Observership Program; the International Residency Program; the International Clinical Electives Program; the International Clinical Fellowship Program, and the Medical Research Fellowship Program. Her educational initiatives include the formation of the Global Health Scholarly Concentration for medical students and residents; continuous global public health rotations; and interdisciplinary medical and surgical missions to include medical, public health, and physician assistant students.

Cheng-Kai Kao, MD, is an academic hospitalist and board-certified clinical informaticist with expertise in digital health and clinical AI, hospital-at-home care, clinical decision support, and healthcare innovation. As Chief Medical Information Officer at UChicago Medicine, Dr. Kao leads major artificial intelligence and digital transformation initiatives, overseeing the evaluation, governance, responsible deployment, and ongoing monitoring of emerging technologies across the enterprise. His broader informatics work focuses on designing clinical decision support tools that enhance patient safety, optimizing workflows to improve efficiency, and making electronic health records more usable while reducing clinicians’ screen time. He also directs clinical informatics courses for the University of Chicago’s medical and master’s programs. As Medical Director of the Office of International Programs, Dr. Kao oversees the care of international patients, works to improve care quality and the patient experience, promotes knowledge exchange, and builds collaborations with academic medical centers and healthcare organizations worldwide. He also developed and leads UChicago Medicine’s Hospital at Home program, an innovative model that brings acute-level care into patients’ homes. In recognition of his leadership in healthcare informatics and patient-centred care, Dr. Kao was named a Top Hospitalist by the American College of Physicians in 2017. He is a frequent speaker on healthcare digital transformation, clinical AI, and hospital-at-home care.

Professor Shafi Ahmed is a world-renowned, multi-award-winning surgeon, author, investor, teacher, futurist, innovator, entrepreneur, humanitarian, and international keynote speaker. He is currently senior partner at Purpose Tech Capital, a VC investing in early-stage health tech start-ups across Europe and recently launched his book INTELLIGENT: The Evolution of AI Transforming Healthcare. He is Professor of Strategic Innovation at Bolton University, Honorary Professor of Practice at UCL Global Business School for Health and Visiting Professor at Imperial College London. His teaching areas are exponential technologies, including AI, the future of healthcare, digital health, innovation, entrepreneurship and digital transformation. He leads the executive education programme for UCL Business School. He is also a faculty member at Stellenbosch Business School, South Africa, and has also been a faculty member at Harvard Medical School and Singularity University.

Anna Titkova, MD, PhD, Professor Assoc., MBA, International Operations Director Pratia, Country Head Ukraine Anna graduated from Kharkiv National Medical University and works as as Assoc. Professor and researcher at Dnipro Institute of Medicine and Public Health. She has a PhD, Master of Medical and Educational Sciences, MBA, completed an internship at Harvard and Yale Universities, and is a qualified international lecturer and senior researcher. In March 2020, Anna opened the Pratia Ukraine LLC and the first SMO clinical research site, Pratia Clinic Ukraine LLC, part of the international site network Pratia under the umbrella of the NEUCA group. Her company works with 10 medical institutions in 3 Ukrainian regions in the clinical trials field. From 2022 she combines her local activites with international operations within the Pratia network of clinical research sites in 8 European countries.

Dr Usamah Mossallam, MD, MBA graduated from the State University of New York Health Sciences Center at Brooklyn. He went on to a combined internal medicine/emergency medicine residency at Christiana Care Health System in Delaware. He was the chief resident for both the categorical and combined residency programs in his fifth and final year. He is board certified in both emergency medicine and internal medicine. After completing his residency in 1999, Dr. Mossallam joined the Department of Emergency Medicine at Henry Ford Hospital where he soon became director of the combined residency programs in emergency medicine/internal medicine and emergency medicine/internal medicine/critical care medicine, as well as the associate residency director of the categorical emergency medicine residency. In early 2006, Dr. Mossallam left Henry Ford Health System and accepted the position of Chairman of Emergency Medicine and associate Chief Medical Officer at the International Medical Center in Jeddah, Saudi Arabia, where he commissioned a new emergency department alongside the commissioning of the International Medical Center hospital. Dr. Mossallam rejoined Henry Ford Health System in late 2008 as the service chief/medical director and division head of the Fairlane Emergency Department within Henry Ford Health System.

In 2011, Dr. Mossallam accepted the position of Chief Medical Officer – associate at Henry Ford Hospital.  

Dr. Michael Hasan Fakih is a pioneering figure in reproductive medicine, fertility innovation, and women’s healthcare, with a distinguished career spanning more than four decades across the United States, the Middle East, and international markets. He is the Founder, Chairman, and Medical Director of Fakih IVF Fertility Center and the Founder and Executive Chairman of Blue Ocean Health. Through his clinical, academic, and entrepreneurial work, Dr. Fakih has played a leading role in expanding access to advanced fertility care and shaping the development of assisted reproductive medicine across the region. Dr. Fakih began his IVF journey in 1987 in Michigan, USA, where he established one of his first fertility centers. He later expanded his work internationally, developing and leading fertility and reproductive healthcare centers across the United States, the United Arab Emirates, Lebanon, Qatar, Oman, and other markets. His healthcare footprint includes IVF Michigan in the United States, Fakih IVF and FIRST IVF across the UAE, fertility centers in Lebanon, Qatar and Oman, and expanding reproductive medicine ventures in the United Kingdom and Europe.A researcher, educator, clinician, and healthcare entrepreneur, Dr. Fakih has authored and co-authored more than 50 peer-reviewed scientific publications and book chapters in reproductive medicine, IVF, embryology, genetics, and fertility preservation. Beyond his clinical achievements, Dr. Fakih has played a transformative role in healthcare leadership across fertility, genomics, women’s health, and medical technology. Through his work, he has helped position the UAE and the wider region as important destinations for advanced reproductive medicine.

Dr. Asma Al-Mannaei is an accomplished Executive Director of Health Life Science Executive Director, Research and Innovation Center in the Department of Health Abu Dhabi, with over 18 years of experience in Public Health, Strategy & Policy, Quality and Healthcare Research and Innovation. With an extensive background in healthcare Management, she is an expert in leading the transformation of healthcare life science in Abu Dhabi. Dr. Al-Mannaei is recognized for her innovative strategies and her ability to drive success in complex projects. She holds an MBBS from UAEU, a Master of Public Health from Johns Hopkins and Executive Education of Advanced Leadership and Management from Harvard Kennedy school.

Doaa Marouf’s career reflects an unwavering dedication to elevating patient care, strengthening strategic partnerships, and ensuring optimal access to innovative medicines. He began his career with Al Khayyat Investments (AKI) in 2002 as a pharmacist. Over the next decade, he honed his expertise across pharmacy operations, retail strategy, and pharmaceutical procurement while simultaneously earning an MBA and then a Ph.D. in Change Management. After a series of management roles in the pharmaceutical sector, he returned to AKI in 2018, eventually becoming CEO of AKI Pharma and BinSina Pharmacy. Today, Doaa actively champions pharmacies as an integral part of any community. He focuses much of his time on nurturing the next generation of pharmacists, anticipating local healthcare needs, and supporting AKI teams to deliver personalised services in health, wellness, and nutrition.

Dr Habiba Al Safar, Dean of the College of Medicine and Health Sciences and Professor of Genomics at Khalifa University, focuses her research on constructing genomic profiles of individuals of Arab descent to identify disease-related genetic segments, particularly those affecting the UAE's local communities. With over 100 publications in Q1 journals, her work includes the first whole-genome sequencing of Emirati subjects, shedding light on genetic diversity and establishing a UAE-specific reference genome. Recognized as an exceptional Arab woman scientist, she has received the International L'Oréal UNESCO Fellowship for Women in Science and the UAE's prestigious First Honour Model award from His Highness Sheikh Mohammed bin Rashid Al Maktoum. Dr Al Safar has been a member of the UAE Science Council since 2016 and recently earned the Khalifa Award for Education for her outstanding university lectures in the UAE.

Majid Kaddoumi is Senior Vice President and President, Europe, Middle East, Africa and Asia Pacific (EurAsia). The region comprises of the Enterprise Accounts & Services for Western Europe, Japan, Australia and New Zealand and the region-led markets of Central and Eastern Europe, Middle East, Africa, Russia and Asia Pacific. Majid serves as a member of Medtronic’s Executive Committee. With over 25 years of experience in operations, services and medical technology, Majid has vast experience in both commercial and operational leadership. Prior to joining Medtronic, Majid was General Manager for General Electric Healthcare (GEHC) for Saudi Arabia. During his tenure at GEHC, he won several President Awards for his achievements and business innovations. Before joining GEHC, Majid was General Manager of a leading distribution and turnkey solutions company based in Saudi Arabia, serving the Middle East. Majid successfully built and established two companies before transitioning into the corporate world.

Tayllit Aherdan is the Vice President and General Manager for Gulf Countries at Eli Lilly, where she leads the company’s business across the United Arab Emirates, Qatar, and Kuwait. Responsible for the full country P&L, she is driving Lilly’s growth strategy across the Gulf while advancing the company’s ambition to be a trusted healthcare partner, accelerating innovation, expanding patient access, and strengthening partnerships across the healthcare ecosystem. Aherdan brings more than 20 years in international biopharmaceutical leadership across North Africa, the Middle East, Asia, Europe and other geographies outside of the United States. She most recently served as Chief Marketing Officer for Lilly China, where she spearheaded the development of industry-leading digital transformation of commercial strategy in one of the world's most competitive healthcare ecosystems. Earlier, as Vice President, International Oncology, she oversaw pre-launch and launch strategies across more than 100 markets spanning Latin America, Europe, the Middle East, Africa, and Asia, including China and Japan, helping accelerate patient access to breakthrough medicines across diverse healthcare systems.

Dr. Haidar Alyousuf is one of the most prominent figures in the UAE healthcare industry and the CEO of iO Health, a UAE-based Cognitive AI company whose platforms are today impacting over 32 million lives across the GCC and beyond. In 2013, Dr. Alyousuf led the design and successful implementation of the health insurance system of the Emirate of Dubai and the mandatory health insurance law for Dubai, law no 11 for 2013, signed by HH Shiekh Mohammed bin Rashid Al Maktoum Vice president of the UAE, Ruler of Dubai, achieving total healthcare coverage for the population in three years and regulating one of the most recognized health systems in region. Before leading iO Health, Dr. Alyousuf built AlFuttaim Health from inception into a 1,000-person integrated healthcare enterprise with around 40 operational business units, and the first internationally accredited primary care group in the UAE.

Since August 2019, Dr Mate has served as Chief Executive Officer of Schön Klinik SE, one of Germany’s top five private hospital groups with a leading position in mental health and a strong footprint in somatic medicine, operating 16 hospitals and 12 outpatient centres in Germany and the UK with around €1bn annual revenue and 12,000 employees. Prior to this, he was Managing Director New Business Areas at Helios Group (09/2018–07/2019), where he developed new segments such as occupational medicine, prevention, and telemedicine/virtual clinic and built international cross-selling opportunities within Helios and Fresenius. From 2010 to 2018, he held successive general management roles at Helios, including Regional Managing Director (Central Region) and Managing Director of Helios Hospital Berlin-Buch, driving multi-year budget overperformance and significant profitability improvements, after earlier leadership positions at Trinity Hospital Cologne combining medical responsibility with finance/controlling, complemented by project work in hospital management in Basel and clinical training at University Hospital Basel across traumatology, general surgery, and emergency medicine.

Uwe Dalichow is a distinguished leader at Bayer Pharma, currently serving as the Head of Region EMA in Berlin and CDH for Bayer Pharmaceuticals Middle East & North Africa. With a career spanning over three decades, Uwe has been instrumental in driving strategic transformation, leading to significant growth and innovation within the pharmaceutical sector. His tenure at Bayer Pharma has been marked by achieving sustainable, above market growth, managing a team of more than 3000 employees. Uwe's journey in the pharmaceutical industry is underpinned by a solid educational foundation, holding a Diploma in Business Administration from the Berlin School of Law & Economics and further enriched by attending corporate business schools at Harvard, IMD, INSEAD, and Duke. His career milestones include pivotal roles such as Country Division Head at Bayer Healthcare in Taiwan, where he led core brand launches in Cardiovascular and Oncology, and Head of Global Marketing Operations at Bayer Pharma in Berlin, where he spearheaded commercial excellence and digital initiatives. Before his impactful contributions at Bayer, Uwe demonstrated exceptional leadership as the Country Division Head for Bayer Schering in Thailand and as Managing Director at PT Schering in Indonesia, where he led a business turnaround and plant divestment. His early career also saw him achieving market leadership in Women's Health as the Business Unit Head at Schering ZAO, Russia.

Khaled Harb holds an Executive MBA from the American University of Beirut (AUB) and a bachelor’s degree in pharmacy and Pharmaceutical Sciences from the Medical Academy in Sofia, Bulgaria (1990). Mr. Harb is a pharmaceutical executive with over three decades of leadership experience in the Middle East, North Africa, and Europe. Currently serving as the Chief Executive Officer of Dar Al Dawa for Development and Investment (DAD) in Amman. Qualified Director by JIoD/IFC. Visionary Pharma Leader driving innovation, strategic growth, transformation, and operational excellence. In addition to serving as CEO, Mr. Harb serves as an active Board Member of Nutridar Jordanian Company and Dar Al Dawa for Veterinary and Agricultural Industries. Mr. Harb serves as a Board Member of the Faculty of Pharmacy at the University of Jordan. And serves as the Chairman of the Board of the Jordanian Association of Pharmaceutical Manufacturers.

Mohamed is the VP General Manager of Amgen in the Middle East & Africa (MEA), with over two
decades of experience in the Pharmaceutical and Biotech fields in various leadership roles in
strategic planning, business development and general management across Europe, Middle East &
Africa.
Additionally, he serves as the chairman of the pharmaceutical industry association in MEA
(PHARMEA). The association contributes significantly to the industry-government dialogue and
policy making in the region enhancing patient access to innovative medicines. Mohamed's
dedication to healthcare is motivated by a commitment to support patients during their most
challenging times.
He is a pharmacist, holds an MBA from Bradford University- UK, and a Six Sigma Black Belt. He is
also a member of the board of several companies in healthcare and technology startup sectors.

Oussama El-Baba is a seasoned healthcare executive with over 30 years of leadership in global healthcare business development, international patient services, and strategic partnerships across the United States, Middle East, North Africa, and Latin America. As Chief Global Destinations Program Officer at UChicago Medicine, he drives the expansion of the institution’s global footprint, deepening partnerships and patient access in key regions including the GCC and Latin America. Before joining UChicago Medicine in 2026, Mr. El-Baba served as Executive Director of Global Business Development at The Paley Orthopedic & Spine Institute, where he launched the Paley Middle East Clinic in Abu Dhabi which served patients from over 20 countries. At New York-Presbyterian Hospital, he held senior leadership roles promoting global services in collaboration with Columbia University and Weill Cornell Medicine. There, he developed and managed strategic initiatives to enhance international patient programs, strengthen partnerships across the Middle East and North Africa, and expand referral networks, significantly increasing the hospital’s regional presence and patient volume. Earlier in his career, Mr. El-Baba founded and led the International Programs Department at Children’s National Medical Center in Washington, D.C., transforming it into a globally recognized pediatric healthcare program. He holds a Master of Health Administration from the University of Missouri and a Bachelor of Science in Biomedical Engineering from Louisiana Tech University. He also holds certifications in effective negotiation and project management from Harvard and George Washington University. His expertise spans complex global partnerships, physician visiting programs, and sustainable growth strategies in diverse international healthcare markets.

Majdi Younis is a seasoned MedTech executive with over 28 years of leadership experience spanning the Middle East, Africa, Central & Eastern Europe, and Russia. He began his career as a medical device distributor in the UAE, developing deep expertise in market access, regulatory affairs, commercial operations, and healthcare market development across diverse and complex healthcare systems. Over the course of his career, Majdi has held senior leadership positions with leading global healthcare organizations, including Medtronic, GE Healthcare, Molnlycke, and Convatec. He has successfully led regional businesses, built high-performing teams, and delivered sustainable growth across both mature and emerging markets. His extensive international experience combines strategic leadership with hands-on operational excellence, enabling him to navigate diverse business environments and evolving healthcare landscapes. Currently serving as General Manager, Middle East & Africa at Convatec, Majdi leads the company’s growth strategy across one of the most dynamic and rapidly evolving healthcare regions in the world. His unique perspective—shaped by experience in multinational corporations, distributor-led markets, and direct commercial operations—provides him with a comprehensive understanding of the opportunities and challenges facing the global MedTech industry.

Dr. Iman Fouad Itani is a distinguished specialist in non-surgical aesthetic medicine and the Medical Director of Lueur Aesthetic Clinic in Dubai. She is widely recognized for her unwavering commitment to patient safety and professional ethics. Holding a Bachelor’s degree in Medicine and Surgery (MBBS), she brings a strong and comprehensive medical foundation to her practice, allowing her to deliver precise, evidence-based care to every patient.

With a deep passion for enhancing natural beauty and promoting overall well-being, Dr. Itani has developed advanced expertise in the diagnosis and management of aesthetic complications. She is particularly known for her skill in ultrasound-guided aesthetic treatments, which she uses to ensure accurate filler placement, enhance treatment safety, and effectively address complications such as vascular occlusion, filler migration, and nodules. Her ability to combine clinical insight with cutting-edge imaging technology has positioned her as a trusted practitioner for complex cases.

In 2021, she founded Lueur Aesthetic Clinic, marking a significant milestone in her career. Guided by her philosophy of prioritizing safety, ethics, and natural results, the clinic is dedicated to offering individualized treatment plans rather than trend-driven procedures. This patient-centric approach reflects Dr. Itani’s commitment to delivering thoughtful, ethical, and science-based aesthetic care.

Expressive, other-centered, and determined to improve the lives of his patients, Dr. Mishal AlQasimi embraced the mandate of creating, developing and running Capital Health on behalf of the Board of Directors at ADCG. He is a Key Opinion Leader in the healthcare industry and the driving force behind the transformation of rehabilitative medicine in Abu Dhabi. Dr. Mishal has influenced the healthcare scene in the region through various national and international presentations, TV appearances and medical workshops. Dr. Mishal received his undergraduate, Medical School and Post-graduate training in the United States. He also achieved the status of Certified Physician Executive by the Certifying Commission in Medical Management from the American Association for Physician Leadership. After completing his residency, Dr. Mishal served as Clinical Instructor at the State University of New York Downtown Medical Center, Director of Newborn Medicine at Lutheran Medical Center and Chief of Medical Education at Lutheran Health Centers. Upon returning to the region, Dr. Mishal served as the Chair of Pediatric Services for the Ambulatory Health Services (AHS) at Abu Dhabi Health Services Company (SEHA) and the Medical Director for the Abu Dhabi Centre for Care and Rehabilitation at the Zayed Higher Organization (ZHO).

Bindhya Cariappa is Executive Director, Research at PureHealth with the mandate to build and expand research across PureHealth entities. She comes from a global drug development and clinical R&D background, having three decades of experience working with Biopharma, CROs and healthcare providers. She has been involved with over 600 clinical research programs across 75 countries and 20 therapeutic areas. She is passionate about building research and innovation capabilities and infrastructure, having done so across organisations and stakeholders in US, Europe, the UK, Latin America, the Middle East, Africa and Asia Pacific. She has a Master’s degree in Pharmacy and has previously worked in Europe, the UK and Asia.

Maya Khouri is Chief Executive Officer of Aesthetics at PureHealth, where she is leading the Group’s beauty and aesthetics vertical with a focus on diagnostics, underlying health and continuity of care - moving beyond individual procedures towards a more integrated approach to aesthetics and healthy ageing. She brings two decades of healthcare experience spanning finance, strategy and operations. Most recently, she served as General Manager of CosmeSurge, where she led the transformation of its multi-specialty aesthetics network of 13 clinics and a hospital across the UAE, repositioning the brand around regenerative aesthetics and inside-out beauty, launching its Integrative Wellness division, and leading the cluster through JCI accreditation. Previously, Maya shaped corporate strategy at NMC Healthcare and led business development at Mubadala Health, spanning acquisitions, government partnerships and the launch of several regional-first service lines. Her work is grounded in the belief that aesthetics can increasingly benefit from a deeper understanding of the factors influencing how people look and age – and that advances in diagnostics and science are creating opportunities for a more personalised, health-informed approach to care. Maya is a Certified Public Accountant and holds a Bachelor of Commerce from McGill University.

Dr. Zain Al Yafei is leading Sakina with the firm belief that mental health care should be accessible, comprehensive, and empathetic. His extensive background in Leadership and genuine passion for excellence have been the driving force behind our organization’s rapid success. Dr. Zain brings over 18 years of healthcare experience in leading and supporting healthcare programs. In his previous role as Chief Medical Officer at Purelab, he was overseeing the medical operations and clinical systems across the laboratories to develop strategies to enhance service delivery and improve the scope of work. He was instrumental in evaluating and optimizing the care management approach, patient, and customer satisfaction, as well as developing processes to assure the appropriateness of lab services. Prior to his role at Purelab, Dr. Zain was the Director of Pharmacy and Allied Health at SEHA, overseeing all allied health services including psychology, social workers, occupational health therapists, and speech-language therapists. He also managed the standardization of care, workforce planning, training, and upskilling programs, and was a member of the DoH COVID-19 Silver task force. Dr. Zain’s previous experience includes his work at SKMC as Technical Director and Deputy Service Lead. Dr. Zain holds a certification from the American Board of Medical Laboratory Immunology, a PhD in Immunology from the University of Bristol, UK, a MSc in Immunology and Immunogenetics from the University of Manchester, UK, and a BSc from the University of Utah, USA.

Albarah El-khani is the Chief Operating Officer of Integrated Health Solutions at M42, where he leads programs that bring together multi-omics, advanced diagnostics, preventive screening, environmental health, biobanking, and precision clinical research to transform population health. With a background in clinical medical microbiology, he combines scientific expertise with strategic delivery on a scale. Albarah has played a pivotal role in building national platforms that shift healthcare upstream, enabling earlier detection, proactive prevention, more accurate diagnosis, and personalized intervention. He has played a central role in advancing the Emirati Genome Program, one of the most ambitious population genomics efforts in the world, and continues to shape initiatives that drive meaningful, system-wide impact. Before that, Albarah served as the Senior Vice President of Operations at M42, where his leadership was instrumental in driving the organization's strategic direction towards precision and personalized medicine. With a rich background spanning over two decades in the healthcare industry, Albarah's journey began with a strong academic foundation in Clinical Medical Microbiology, obtained from Westminster University in London. His career has been marked by significant contributions and leadership roles across the UK and GCC regions, demonstrating a profound commitment to healthcare excellence and innovation. Notably, Albarah served as the Chief Operating Officer at the National Reference Laboratory in the UAE, where his strategic initiatives significantly contributed to operational efficiencies and elevated standards in healthcare practices. This role underscored his ability to navigate complex healthcare landscapes and implement transformative strategies that enhance patient care and organizational performance. Currently, at M42, Albarah leverages his extensive experience and operational acumen to lead the organization's efforts in adopting cutting-edge approaches to healthcare. His work is focused on the integration of precision and personalized medicine into mainstream healthcare delivery, aiming to set new benchmarks for quality and efficiency.

Nalla Karunanithy is the CEO of Aster Digital Health & Omnichannel, the digital business of Aster DM Healthcare, where he leads myAster, the group’s platform for digital health, wellness and beauty in the GCC, and the group’s AI and digital transformation across all the verticals. He has built digital businesses across more than fifty countries, and across retail, banking and real estate before moving into healthcare. He began at Rocket Internet as global Chief Product Officer, first in Sydney and then in Berlin, building and scaling e-commerce ventures across the group’s portfolio of companies. He then joined McKinsey & Company, based in Berlin, working on digital business building and transformation strategy. He moved to Dubai with Majid Al Futtaim, leading the digital team behind Carrefour’s e-commerce and store technology and launching the region’s first checkout-free grocery store and its first automated fulfilment warehouses. Health data is usually scattered. A prescription sits in one system, a lab result in another, a clinic visit in a third, a wearable reading in a fourth, and none of them talk to each other. Nalla’s work at Aster is about connecting those points into one record per person, so the platform can act on what it already knows rather than asking the customer to explain themselves again. myAster covers medicine delivery, doctor consultations, lab tests at home, vitamins and supplements, and beauty and personal care. Thrive by myAster, its preventive health product, measures a hundred biomarkers from an at-home blood draw and returns a biological age score, an action plan and a doctor consultation. The platform runs on top of Aster’s hospitals, clinics, pharmacies and labs, which gives it a physical layer that app-only competitors do not have. A patient can book a doctor in the app and see them in a clinic, order a prescription and collect it in a pharmacy, or have a nurse draw blood at home and read the results on a phone. Nalla owns that day-to-day experience end to end

Arda Arat is currently serving as the General Manager for HaleonGulf & Near East (GNE). He is a strategic leader with over two decades of finance experience. Having previously served as a Business Unit Finance Head for Middle East Africa (MEA) at Haleon, Arda has successfully led and supported multiple initiatives to drive growth, profitability, and innovation across the MEA region, such as launching new products, expanding into new markets, optimizing pricing strategies, executing mergers and acquisitions, and implementing process improvements. Through his role at Haleon, Arda’s mission is to improve the health and well-being of millions of people in MEA and beyond.

Alice Yammine Boueiz is one of the most prominent healthcare leaders in the Arab world and a driving force behind the regional transformation of healthcare systems. As CEO of the Arab Hospitals Federation, she has dedicated over 25 years to building bridges across countries, sectors, and institutions reshaping the healthcare landscape through innovation, equity, and strategic collaboration. With a proven track record in health systems, healthcare policy, and cross-border partnerships, Alice is widely regarded for her visionary thinking, collaborative leadership, and unwavering commitment to accessibility, sustainability, equity, and innovation. Her leadership has been instrumental in modernizing healthcare governance, digitizing operational systems, and embedding quality and excellence at the heart of Arab institutions

Ahmad Wasef Ibrahim Alahmad Chief Executive Officer, Future Health GCC Ahmad Alahmad is the Chief Executive Officer of Future Health GCC, a pioneering biotechnology company specializing in stem cell banking and regenerative medicine. Based in Dubai Healthcare City, Future Health GCC operates one of the region’s most advanced GMP-certified facilities, dedicated to stem cell processing, cryogenic storage, and next-generation cell and exosome therapies. Under Ahmad’s visionary leadership, the company has achieved multiple international accreditations, including ISO 9001 (Quality Management), ISO 15189 (Medical Laboratories), and GMP (Good Manufacturing Practice). Driven by a passion for innovation and scientific excellence, Ahmad is leading Future Health GCC’s mission to transform the landscape of regenerative and personalized medicine, advancing safe, ethical, and cutting-edge healthcare solutions across the GCC and beyond.

Miguel Angel Villalonga is the Chief Executive Officer of PureCS, the technology arm of PureHealth Group. With more than 30 years of international experience in the ICT industry, he has led technology, cloud, digital transformation, and systems integration businesses across Europe and the Middle East. Prior to PureCS, Miguel held senior leadership positions at e& enterprise, including COO and CEO of its Cloud and IoT businesses, and previously served as CEO of Emitac Enterprise Solutions. He holds a Master's degree in Computer Science, an Executive MBA from IE Business School, and executive qualifications in Digital Transformation, Corporate Governance, and Venture Capital.

Dr Yazan Aljabery is a Consultant Cardiac Surgeon and Clinical Assistant Professor who bridges advanced cardiac surgery with prevention, lifestyle medicine, and healthcare innovation. As the first cardiac surgeon outside the United States to become board-certified in Lifestyle Medicine, he serves as Founding Board Member and Chairperson of the Emirates Lifestyle and Longevity Medicine Society. His work combines AI, smart wearables, 3D printing, and AI governance to shape the future of healthcare. He is currently pursuing a Master’s in Innovation Management and AI Governance at MBRSG and has been recognised with multiple national and international awards for his contributions to medicine and innovation.

Dr. Mohamed Alnadi is Chairman of Alnadi Pharma and Vice President of International Expansion and Partnerships for the MENA and Africa region at Dawah Pharma. He is also Co-Founder and Board Member of VitaBahn. With more than 25 years of experience across the pharmaceutical, healthcare, international trade, and manufacturing sectors, Dr. Alnadi has led international expansion, export operations, strategic partnerships, and market development across more than 60 countries. Since 2002, he has led Alnadi Pharmacy Company, contributing to its development within the pharmaceutical and healthcare sectors. He previously served as Managing Director of EgyBelg for Industrial Investment, with a focus on biotechnology and enzyme production, and has also held senior leadership responsibilities within the food manufacturing sector, supporting regional and international growth. Dr. Alnadi holds a Bachelor’s degree in Pharmacy from Cairo University and a Business Administration Diploma from the American University in Cairo.

Khaled Ateeq Aldhaheri serves as the Chief Executive Officer of the National Insurance Company – Daman, a subsidiary of PureHealth Group, the largest healthcare group in the Middle East . Aldhaheri brings a wealth of skills to the role and is a prominent healthcare industry veteran in the UAE, with more than two decades of high-level experience in healthcare, business, and finance. With an exceptional record of accomplishment, he is a pioneering leader with a legacy for optimising business operations, cultivating business growth, boosting revenue streams and promoting sustainable business growth. His combined strategic direction, financial acumen, and visionary approach have created significant value within the organisations he has served at a national level. Prior to his current role, he held several strategic leadership positions in Abu Dhabi Health Services (SEHA), a subsidiary of the PureHealth Group, including the positions of Chief Commercial Officer and Chief Financial Officer.

Bringing nearly three decades of experience in digital transformation, artificial intelligence and technology leadership across financial services, entertainment, telecommunications and healthcare. Throughout his career, Aamer has led large-scale digital transformation programmes, harnessing emerging technologies to modernise organisations, unlock new capabilities and build future-ready digital ecosystems. His expertise spans digital platforms, AI adoption, technology modernisation and the development of solutions that translate innovation into meaningful business and customer outcomes. Aamer holds a degree in Electrical Engineering and has completed the Advanced Management Program (AMP) at Harvard Business School. Combining deep technical expertise with strategic leadership, he has built a career at the intersection of technology, innovation and enterprise transformation.

At PURA, Aamer is focused on advancing the role of digital technology and AI in healthcare, helping shape more connected, intelligent and seamless healthcare experiences that support PureHealth’s ambition to transform the future of health.

Dr. Khadija Al Marashda is the Chief Executive Officer of SEHA CLINICS, the trusted multi-specialty primary care provider in the emirate of Abu Dhabi and one of the UAE’s largest outpatient healthcare networks. She leads a network of 40+clinics, 250+ school health clinics and services, and 9 mobile healthcare units across Abu Dhabi, Al Ain and Al Dhafra, with 900+ physicians supporting more than 4 million patient visits annually and delivering accessible, convenient, preventive and multispecialty care closer to communities. Combining clinical expertise with an MBA in Strategic Management, Dr. Khadija is recognised for advancing integrated, patient-centric care shaped around the needs and cultural context of the communities served by SEHA CLINICS.

Under her leadership, the network has continued to expand with new clinic openings, alongside growth in specialty services, with visits for specialty care more than doubling. SEHA CLINICS has also recorded improvements in patient experience and operational performance, achieving an NPS of 74+. Dr. Khadija has also championed innovation in community healthcare through the introduction of AI-enabled diagnostic initiatives and digitally integrated care solutions, supporting the UAE’s wider vision for more connected, preventive and technology-enabled healthcare delivery.

Ahmad Al Ahmad is the CEO and Founder of Future Health GCC and a driving force behind the growth of stem cell banking, regenerative medicine, and advanced healthcare solutions across the Middle East. Born in Jordan and raised in Saudi Arabia, Ahmad studied at the American University of Beirut, Lebanon, and the University of Nottingham Science Park, UK, before relocating to Dubai in 2014. There, he successfully established Future Health’s first GMP laboratory for stem cell processing and storage in the UAE. Over the years, Ahmad has played a key role in advancing awareness and accessibility of umbilical cord blood and tissue banking, dental pulp banking, stem cell storage, and diagnostic testing across the region. He was also among the first to offer families in the Middle East the added security of dual storage across Future Health’s facilities in the UK, Switzerland, and Dubai. In 2023, under his leadership, Future Health opened an advanced GMP-grade cleanroom facility in Dubai Healthcare City, strengthening the company’s capabilities beyond stem cell banking into stem cell duplication, expansion and manufacturing, alongside state-of-the-art cryogenic storage.